Public Sector Pension Investment Board Has $88.84 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• Public Sector Pension Investment Board has reduced its stake in Intuitive Surgical by 10.6%, now owning 179,380 shares valued at $88.8 million.
• Institutional investors and hedge funds hold 83.64% of Intuitive Surgical's stock, with significant stakings being added or adjusted by various firms.
• Wall Street analysts largely favor Intuitive Surgical with a consensus rating of "Moderate Buy" and a target price of approximately $595.95.

Public Sector Pension Investment Board lowered its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 10.6% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 179,380 shares of the medical equipment provider's stock after selling 21,183 shares during the quarter. Public Sector Pension Investment Board owned about 0.05% of Intuitive Surgical worth $88,842,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of ISRG. Chilton Capital Management LLC lifted its holdings in shares of Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after buying an additional 43 shares in the last quarter. Parvin Asset Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter worth $26,000. Global Financial Private Client LLC increased its position in shares of Intuitive Surgical by 253.3% in the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares during the period. Elite Financial Inc. bought a new position in shares of Intuitive Surgical in the first quarter worth $26,000. Finally, LFA Lugano Financial Advisors SA bought a new position in shares of Intuitive Surgical in the first quarter worth $30,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, insider Gary S. Guthart sold 7,893 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $498.64, for a total value of $3,935,765.52. Following the transaction, the insider directly owned 13,187 shares of the company's stock, valued at approximately $6,575,565.68. The trade was a 37.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president directly owned 353 shares in the company, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,881 shares of company stock valued at $7,920,634. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Trading Up 1.3%

ISRG stock traded up $6.34 during trading on Tuesday, hitting $478.19. The company had a trading volume of 1,529,402 shares, compared to its average volume of 2,211,435. The business has a 50-day moving average of $513.42 and a 200-day moving average of $527.10. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The stock has a market cap of $171.42 billion, a PE ratio of 66.69, a PEG ratio of 4.95 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The business had revenue of $2.44 billion for the quarter, compared to analysts' expectations of $2.35 billion. During the same period in the prior year, the business posted $1.78 earnings per share. The firm's revenue was up 21.4% on a year-over-year basis. Research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of recent analyst reports. Royal Bank Of Canada raised their price target on Intuitive Surgical from $605.00 to $615.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 23rd. Evercore ISI raised their price target on Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Truist Financial raised their price target on Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Robert W. Baird decreased their price target on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Finally, UBS Group lifted their target price on Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.